Bausch Health (BHC) recently stopped participating in Medicaid and 340B, a federal government drug discount scheme, STAT’s Ed Silverman reports. A spokeswoman said the company “remains fully committed” to patients who are prescribed its medicines and to compensate a patient assistance program was “enhanced” with zero out-of-pocket costs for covered medicines and free home delivery.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health announces results of special meeting of shareholders
- Bausch Health’s Solta Medical featured on ‘The Balancing Act’
- Bausch Health’s OraPharma introduces ‘OraTalks’ podcast
- Bausch Health completes acquisition of DURECT Corporation
- Solta Medical surpasses 5M skin tightening treatments with Thermage